ATE269078T1 - Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems - Google Patents

Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems

Info

Publication number
ATE269078T1
ATE269078T1 AT01986458T AT01986458T ATE269078T1 AT E269078 T1 ATE269078 T1 AT E269078T1 AT 01986458 T AT01986458 T AT 01986458T AT 01986458 T AT01986458 T AT 01986458T AT E269078 T1 ATE269078 T1 AT E269078T1
Authority
AT
Austria
Prior art keywords
disorders
treatment
production
nervous system
central nervous
Prior art date
Application number
AT01986458T
Other languages
English (en)
Inventor
Wayne Everett Childers
Michael Gerard Kelly
Sharon Joy Rosenzweig-Lipson
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Application granted granted Critical
Publication of ATE269078T1 publication Critical patent/ATE269078T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Endocrinology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
AT01986458T 2000-11-28 2001-11-27 Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems ATE269078T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US25330100P 2000-11-28 2000-11-28
US29781401P 2001-06-13 2001-06-13
PCT/US2001/043160 WO2002044142A2 (en) 2000-11-28 2001-11-27 Piperazine derivatives, their preparation and their use for treating central nervous system (cns) disorders

Publications (1)

Publication Number Publication Date
ATE269078T1 true ATE269078T1 (de) 2004-07-15

Family

ID=26943115

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01986458T ATE269078T1 (de) 2000-11-28 2001-11-27 Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems

Country Status (24)

Country Link
US (3) US6469007B2 (de)
EP (1) EP1339406B1 (de)
JP (1) JP4198989B2 (de)
KR (1) KR100835552B1 (de)
CN (1) CN100352437C (de)
AR (1) AR035603A1 (de)
AT (1) ATE269078T1 (de)
AU (2) AU2002237654B2 (de)
BR (1) BR0115609A (de)
CA (1) CA2428039C (de)
DE (1) DE60103927T2 (de)
DK (1) DK1339406T3 (de)
EA (1) EA005925B1 (de)
ES (1) ES2222401T3 (de)
HU (1) HUP0400551A2 (de)
IL (1) IL156098A0 (de)
MX (1) MXPA03004677A (de)
NO (1) NO325501B1 (de)
NZ (1) NZ526150A (de)
PL (1) PL363219A1 (de)
PT (1) PT1339406E (de)
TR (1) TR200401546T4 (de)
TW (1) TWI224102B (de)
WO (1) WO2002044142A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6432826B1 (en) * 1999-11-29 2002-08-13 Applied Materials, Inc. Planarized Cu cleaning for reduced defects
US20060287335A1 (en) 2000-11-28 2006-12-21 Wyeth Serotonergic agents for treating sexual dysfunction
US20060223824A1 (en) * 2000-11-28 2006-10-05 Wyeth Serotonergic agents
ATE424825T1 (de) 2001-07-20 2009-03-15 Psychogenics Inc Behandlung von hyperaktivitätsstörungen und aufmerksamkeitsdefiziten
EP1483256A2 (de) 2002-03-12 2004-12-08 Wyeth Verfahren zur herstellung chiraler 1,4-disubstituierter piperazine
CA2477892C (en) 2002-03-12 2010-11-23 Gregg Brian Feigelson Process for synthesizing chiral n-aryl piperazines
US7091349B2 (en) 2002-03-12 2006-08-15 Wyeth Process for synthesizing N-aryl piperazines with chiral N′-1-[benzoyl(2-pyridyl)amino]-2-propane substitution
US7361773B2 (en) 2002-03-12 2008-04-22 Wyeth Preparation of N1-(2'-pyridyl)-1,2-propanediamine sulfamic acid and its use in the synthesis of biologically active piperazines
GB0219961D0 (en) * 2002-08-28 2002-10-02 Pfizer Ltd Oxytocin inhibitors
WO2004082686A2 (en) * 2003-03-13 2004-09-30 Dynogen Pharmaceuticals, Inc. Use of compounds with combined 5-ht1a and ssri activities to treat sexual dysfunction
US20070099931A1 (en) * 2004-03-19 2007-05-03 Wyeth Pharmaceutical dosage forms and compositions
US20050215561A1 (en) * 2004-03-19 2005-09-29 Krishnendu Ghosh Pharmaceutical dosage forms and compositions
US20050209245A1 (en) * 2004-03-19 2005-09-22 Wyeth Process for preparing N-aryl-piperazine derivatives
KR100646337B1 (ko) * 2004-06-30 2006-11-23 주식회사 롯데기공 보일러의 누수 감지방법
ATE469174T1 (de) 2004-10-15 2010-06-15 Us Gov Health & Human Serv Amphipathische helixförmige multidomänenpeptide und verfahren zu deren anwendung
CN101137648A (zh) * 2005-03-01 2008-03-05 惠氏公司 结晶和非晶4－氰基－n－{(2r)－2－[4－(2,3－二氢－苯并[1,4]二氧杂环己烯－5－基)－哌嗪－1－基]－丙基}－n－吡啶－2－基－苯甲酰胺盐酸盐
TW200800959A (en) * 2005-06-10 2008-01-01 Wyeth Corp Piperazine-piperidine antagonists and agonists of the 5-HT1a receptor
WO2006138549A1 (en) * 2005-06-17 2006-12-28 Wyeth Tricyclic compounds useful as serotonin inhibitors and 5-ht1a agonists and antagonists
JP2009524680A (ja) * 2006-01-26 2009-07-02 ザ ユニバーシティ オブ ロチェスター 血液脳関門におけるアミロイドβペプチド／ＲＡＧＥ相互作用の阻害
TW200811144A (en) * 2006-06-09 2008-03-01 Wyeth Corp Crystalline forms of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline
TW200808740A (en) * 2006-06-09 2008-02-16 Wyeth Corp Succinate salts of 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline and crystalline forms thereof
TW200808741A (en) * 2006-06-09 2008-02-16 Wyeth Corp 6-methoxy-8-[4-(1-(5-fluoro)-quinolin-8-yl-piperidin-4-yl)-piperazin-1-yl]-quinoline hydrochloric acid salts
CL2007003410A1 (es) * 2006-11-28 2008-04-11 Wyeth Corp Compuestos derivados de 5-fluoro-8-{4-[4-(6-metoxiquinolin-8-il)piperazin-1-il]piperidin-1-il}quinolina; procedimiento de preparacion; compuestos intermediarios; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento de trast
TW200901974A (en) * 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
WO2009129263A1 (en) * 2008-04-15 2009-10-22 The Government Of The Usa As Represented By The Secretary Of The Department Of Health & Human Serv. Peptides promoting lipid efflux via abca1 and activating a lipoprotein lipase

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9201991A (es) 1991-05-02 1992-11-01 Jonh Wyeth & Brother Limited Derivados de piperazina y procedimiento para su preparacion.
GB9514901D0 (en) 1995-07-20 1995-09-20 American Home Prod Piperazine derivatives

Also Published As

Publication number Publication date
EA200300619A1 (ru) 2003-10-30
EP1339406A2 (de) 2003-09-03
HUP0400551A2 (en) 2006-02-28
DK1339406T3 (da) 2004-09-27
JP4198989B2 (ja) 2008-12-17
US6469007B2 (en) 2002-10-22
US6586436B2 (en) 2003-07-01
HK1057864A1 (en) 2004-04-23
PL363219A1 (en) 2004-11-15
JP2004520289A (ja) 2004-07-08
US20030216408A1 (en) 2003-11-20
AU3765402A (en) 2002-06-11
DE60103927D1 (de) 2004-07-22
EA005925B1 (ru) 2005-08-25
KR20030051879A (ko) 2003-06-25
AU2002237654B2 (en) 2005-07-28
EP1339406B1 (de) 2004-06-16
IL156098A0 (en) 2003-12-23
US20030022901A1 (en) 2003-01-30
CA2428039A1 (en) 2002-06-06
AR035603A1 (es) 2004-06-16
NO325501B1 (no) 2008-05-26
CA2428039C (en) 2011-08-09
PT1339406E (pt) 2004-10-29
NZ526150A (en) 2004-11-26
WO2002044142A3 (en) 2002-08-08
US20020107254A1 (en) 2002-08-08
TR200401546T4 (tr) 2004-09-21
KR100835552B1 (ko) 2008-06-09
TWI224102B (en) 2004-11-21
CN1477961A (zh) 2004-02-25
WO2002044142A2 (en) 2002-06-06
BR0115609A (pt) 2003-11-11
DE60103927T2 (de) 2005-06-23
US7026320B2 (en) 2006-04-11
CN100352437C (zh) 2007-12-05
NO20032390L (no) 2003-07-22
MXPA03004677A (es) 2003-09-05
NO20032390D0 (no) 2003-05-27
ES2222401T3 (es) 2005-02-01

Similar Documents

Publication Publication Date Title
ATE269078T1 (de) Piperazin derivate, deren herstellung und deren verwendung in der behandlung von störungen des zentralnervensystems
DE602004015269D1 (de) Piperazin derivate und ihre verwendung für die behandlung von neurologischen und psychiatrischen krankheiten.
ATE420866T1 (de) 4-(phenylpiperazinylmethyl) benzamidderivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen
DE60234116D1 (de) Piperidin mch antagonisten und ihre verwendung in der behandlung von obesität und störungen des zentralnervensystems
NO20014303D0 (no) JAK-3-inhibitorer for behandling av allergiske lidelser
DE60234269D1 (de) Substituierte aryl 1,4-pyrazin derivate
NO20031903L (no) Nye amidoalkylpiperidin- og amidoalkylpiperazinderivater for anvendelse vedbehandling av nervesystemlidelser
DE60233265D1 (de) 5-sulfanyl-4h-1,2,4-triazolderivate und deren verwendung zur behandlung von somatostatine vermittelten krankheiten
NO20022585L (no) Pyrrolidinacetamidderivat alene eller i kombinasjon for behandling av forstyrrelser i sentralnervesystemet
ATE415392T1 (de) Pyrimidinonderivate und deren verwendung bei der behandlung von atherosklerose
ATE310003T1 (de) Benzodiazepin-derivate, deren herstellung und anwendung
EE200200442A (et) Piperasiini ja piperidiini derivaadid neuronaalsete kahjustuste raviks
ATE411801T1 (de) Verwendung von oxindol-derivaten bei der behandlung von demenzbedingten krankheiten, alzheimer-krankheit und erkrankungen im zusammenhang mit glykogen-synthase-kinase-3
ATE420097T1 (de) Substituierte sapogenine und ihre verwendung
ATE316529T1 (de) Substituierte pyridylmethylpiperazin- und piperidinderivate, deren herstellung und deren verwendung in der behandlung von erkrankungen des zentralnervensystems (zns)
ATE276245T1 (de) Indolderivate und deren verwendung zur behandlung von u.a. osteoporosis
DE60318839D1 (de) 2,6-chinolinyl- und 2,6-naphthylderivate und deren verwendungen zur behandlung von vla-4 bezogenen krankheiten
DE69901177D1 (de) Platinkomplex, dessen herstellung und dessen therapeutische verwendung
ATE263564T1 (de) Verwendung von 1-(4-(5-cyanoindol-3yl)butyl)-4-(2-carbamoylben ofuran-5-yl)piperazin und dessen physiologisch akzeptablen salzen zur behandlung von bipolaren krankheiten und manie
ATE275400T1 (de) Verwendung von melatonin zur behandlung der androgenetischen und diffusen alopezie vom weiblichen typ
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE336491T1 (de) Piperazinylacylpiperidinderivate, deren herstellung und deren therapeutische anwendung
DE69523654D1 (de) Verwendung von Ascorbyl-gamma-Linolenat und von Ascorbyl-dihomo-gamma-linolenat zur Behandlung von Asthma, Krebs, kardiovaskulären und inflammatorischen Erkrankungen
ATE412635T1 (de) Diphenylpyridinderivate, deren herstellung und deren therapeutische anwendung
DE60205894D1 (de) 4-(phenyl-piperidin-4-ylidenmethyl)-benzamid-derivate und deren verwendung zur behandlung von schmerzen, angst oder gastrointestinalen störungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1339406

Country of ref document: EP

REN Ceased due to non-payment of the annual fee